Lithospermum Ointment Veterinary Grade API is a standardized lipophilic extract of Lithospermum erythrorhizon Siebold & Zucc. root, supplied as a bulk active substance for formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The trade designation includes the word “ointment,” but the material is not a finished semisolid dosage form; it is a veterinary-grade botanical extract whose principal constituents—shikonin, acetylshikonin, isobutyrylshikonin, and β,β-dimethylacrylshikonin—are quantified together as total shikonin derivatives. Because no harmonized veterinary monograph assigns a single model code to this material, manufacturers use supplier-specific identifiers that separate the micronized injection grade, the spray-dried oral-powder grade, and the granular premix grade. The product differs from crude root powder in that it is concentrated and controlled for assay, residual solvents, elemental impurities, and microbial burden; it differs from isolated shikonin in that the natural acylated derivative profile is retained.

What Specifications Govern a Multi-Dosage-Form Lithospermum API?

Specification setting for this extract requires a botanical monograph approach rather than a single-compound monograph because the active fraction is a set of related naphthoquinones. The certificate of analysis should contain identification, assay, loss on drying, residue on ignition, residual solvents, elemental impurities, microbial limits, and particle-size distribution. Compliance with compendial and veterinary guidance such as USP <561>, VICH GL2, and VICH GL18 is expected, though numerical acceptance criteria are supplier-dossier values and are not automatically transferable across extraction routes. Table 1 presents a representative specification matrix for a multi-dosage-form API; commercial batches may apply tighter internal limits for injection use.

Table 1. Representative specification matrix for Lithospermum veterinary-grade API.

The assay is expressed as total shikonin because the acylated derivatives may co-elute or undergo hydrolysis under reversed-phase conditions; reporting only free shikonin would under-represent the active fraction. Extraction-route differences—supercritical carbon dioxide versus ethanol-water fractionation—can shift the ratio of acetylshikonin to β,β-dimethylacrylshikonin without changing total naphthoquinone content. Published data for this specific configuration is limited; therefore, equivalence of dissolution, pharmacokinetics, or feed stability across extraction routes should be confirmed in the target dosage form rather than inferred from the assay alone.

Dry blending for tablets, capsules, powders, and premixes is controlled primarily by segregation risk at low active inclusion rates, not by chemical instability alone. A feed premix containing 10 g API per 100 kg finished feed requires carrier adsorption or spray-dried granulation; direct addition of the lipophilic powder to cereal-based feed produces assembly segregation due to density and electrostatic differences. Spray-dried material with D90 ≤ 75 µm and bulk density 0.30–0.45 g/cm³ is generally more dispersible than the paste-form extract. For tablet and capsule manufacture, dry granulation by roll compaction is preferred over aqueous wet granulation because the poorly water-wettable extract forms sticky agglomerates when water is sprayed directly onto the powder mass. Colloidal silicon dioxide at 0.5–1.0% w/w and magnesium stearate at 0.5% w/w are typical powder-flow and lubrication additions, but actual levels require ribbon density and tablet hardness optimization under target press speed.

Table 2. Dosage-form-specific processing thresholds for Lithospermum veterinary-grade API.

These thresholds are not compendial acceptance criteria; they are process-development starting points that must be confirmed by mixer validation, powder rheology, and product-specific stability studies. Batch-to-batch variability in the natural ratio of acyl derivatives changes the melting point and wettability of the extract; therefore, a change in extract lot may require adjustment of granulating fluid volume or carrier ratio.

When Parenteral Administration Demands Sterility and Low Endotoxin Burden

Parenteral use imposes the most stringent process controls because the extract is practically insoluble in water and contains heat-sensitive naphthoquinones. Sterility must be demonstrated by USP <71>; bacterial endotoxin limits are product-specific, with a common small-volume injectable target of NMT 0.5 EU/mg, though this value is not a universal pharmacopoeial requirement. Terminal moist-heat sterilization at 121°C for 15 min should be adopted only after forced degradation data demonstrate no loss of total naphthoquinones outside specification; published data for this specific configuration is limited, so pilot-scale thermal challenge is required before selecting a sterilization cycle.

Formulation approaches for injectable solutions include cosolvent systems with ethanol, propylene glycol, or PEG 300, or inclusion complexation with hydroxypropyl-β-cyclodextrin. Filtration of lipophilic cosolvent solutions through nylon membranes can remove the active by adsorption; PVDF or PTFE membranes are preferred. The solution pH should be maintained in the acidic-to-neutral range; alkaline pH above 7.0 promotes ionization of phenolic hydroxyl groups and an irreversible color shift associated with degradation. Nitrogen overlay and amber glass are standard controls for oxygen and light sensitivity. For suspension injections, micronized API at D90 ≤ 15 µm must also meet particulate matter and syringeability requirements; particle growth during storage is a critical failure mode that requires subvisible particle counting by USP <788>.

Chemical Incompatibilities and Degradation Pathways in Aqueous Veterinary Formulations

Shikonin and its acyl derivatives are sensitive to light, alkaline pH, oxidative radicals, and heavy metal ions. In aqueous solution, the naphthoquinone ring undergoes pH-dependent enolization; at pH above 7.0, the molecule becomes more polar and susceptible to polymerization. In acidic media below pH 3.0, acid-catalyzed hydrolysis of acetylshikonin can increase free shikonin, changing the chromatographic fingerprint without necessarily reducing total assay. For solid oral dosage forms, these degradation pathways are slower; however, direct contact with iron oxide pigments, high-surface-area silicates, or residual moisture above 5.0% can accelerate oxidation during accelerated stability storage at 40°C/75% RH.

This sensitivity profile differentiates the product from purified synthetic shikonin, which may lack the acylated derivatives that buffer the parent molecule against rapid hydrolysis, and from water-soluble botanical extracts that can be incorporated without cosolvent systems. Unlike crude root powder, the veterinary-grade API is controlled for microbial limits, residual solvents, and elemental impurities; unlike many synthetic antimicrobials, its activity is not expressed as a single minimum inhibitory concentration because the ratio of shikonin to acetylated derivatives influences potency. The material should not be combined with alkaline buffering agents, strong oxidizing agents, or uncoated metal surfaces during liquid manufacturing; compatibility with antioxidants should be confirmed by peroxide challenge testing.

If compared with Centella asiatica triterpenes or aloe vera polysaccharides, Lithospermum naphthoquinones are more hydrophobic and require non-aqueous solvent or cyclodextrin systems. If compared with purified shikonin, the natural extract has a multi-component profile that may reduce recrystallization but complicates assay standardization. If compared with synthetic dye or antibiotic APIs, it is not a single defined molecule; therefore batch consistency must be managed through chromatographic fingerprinting rather than a single peak assay alone.

Tablets and capsules containing Lithospermum extract are usually developed as non-sterile oral dosage forms. Because the API is lipophilic and poorly water-wettable, direct compression is suitable only for low-dose formulations in which the API is pre-blended with lactose monohydrate or microcrystalline cellulose and a glidant such as colloidal silicon dioxide. Uniformity of dosage units should meet USP <905>; for low-dose tablets, content uniformity acceptance value should not exceed 15. Capsule filling can use the same dry granulation when powder flow is adequate; dissolution testing may require a surfactant-containing medium to discriminate batch variability. Powders and granules are typically dry-blended with dextrose monohydrate or maltodextrin and packaged in light-resistant sachets. Premixes require mixer validation under production-scale ribbon or paddle mixers; coefficient of variation of the active marker should be ≤ 5.0% in at least 10 spot samples before release. For medicated feed in the European Union, Regulation (EU) 2019/4 imposes maximum carryover limits for active substances; therefore equipment cleaning validation must demonstrate that residual shikonin in subsequent batches does not exceed the assigned carryover limit. Oral solutions require a hydroalcoholic vehicle or emulsifier system because the aqueous solubility of total shikonins is below 0.1 mg/mL in unbuffered water; published data for exact aqueous solubility varies with derivative composition, so a formulation-specific saturation study should be performed. Precipitation during storage, rather than chemical degradation alone, is the principal shelf-life limit for these solutions.